REG - Oxford Biomedica PLC - Grant of options

Oxford BioMedicaAnnouncement

22/11/2024 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241122:nRSV3867Na&default-theme=true

RNS Number : 3867N  Oxford Biomedica PLC  22 November 2024

 

Grant of options

 

Oxford, UK - 22 November 2024: Oxford Biomedica plc ("OXB" or the "Company";
LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today
announces the grant of an LTIP award under the OXB 2024 Long Term Incentive
Plan ("LTIP") to Mark Caswell, Site Head of UK Operations.

 

In consideration of the grant of the award, an RSU award previously granted to
Mark Caswell on 3 October 2024 has been cancelled.

 

As with the LTIP awards granted on 3 October 2024 and in line with best
practice, the award was scaled back by 20%. The award is subject to the same
performance conditions as the awards granted on 3 October 2024.

The award will "vest" on 3 October 2027 to the extent determined by reference
to the assessment of the performance conditions and will be released at
vesting.

The Notification of Dealing Forms set out below are provided in accordance
with the requirements of the EU Market Abuse Regulation.

 

Notification of Dealing Form (1 of 2)

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Mark Caswell
 2.  Reason for the notification
 a)  Position/status                          Site Head of UK Operations
 b)  Initial notification/                    Amendment

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code                      ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Cancellation of RSU award over 23,352  shares granted under the Company's
                                              Long Term Incentive Plan.
 c)  Price(s) and volumes(s)                  RSU Award

Price  Volume (number of shares originally subject to the RSU Award)
                                              Nil    23,252
 d)  Aggregated information

     -    Aggregate volume                    23,352

     -    Price

                                              N/A
 e)  Date of the transaction                  2024-11-22
 f)  Place of the transaction                 Outside of trading venue

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

23,352

 

 

N/A

e)

Date of the transaction

2024-11-22

f)

Place of the transaction

Outside of trading venue

Notification of Dealing Form (2 of 2)

 

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Mark Caswell
 2.  Reason for the notification
 a)  Position/status                          Site Head of UK Operations
 b)  Initial notification/                    Initial notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code                      ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Grant of 53,724 LTIP award over Ordinary Shares under the Company's Long Term
                                              Incentive Plan.
 c)  Price(s) and volumes(s)                  LTIP Award

Price  Volume
                                              Nil    53,724
 d)  Aggregated information

     -    Aggregate volume                    53,724

     -    Price

                                              N/A

 e)  Date of the transaction                  2024-11-22
 f)  Place of the transaction                 Outside of trading venue

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

53,724

 

 

N/A

 

e)

Date of the transaction

2024-11-22

f)

Place of the transaction

Outside of trading venue

 

 

-Ends-

 

Enquiries:

 

 Oxford Biomedica plc:

 Natalie Walter, Company Secretary   Tel: +44 (0)1865 783 000

 

About OXB

 

OXB (LSE: OXB) is a quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25
years of experience in viral vectors; the driving force behind the majority of
cell and gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus and other viral vector types. OXB's world-class capabilities
span from early stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
Tetravecta™ system), dual plasmid system for AAV production, suspension and
perfusion process using process enhancers and stable producer and packaging
cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBSBDBSUDDGSD